These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27416917)

  • 1. Outsource-ability of high-resolution MS-based DMPK assays.
    Rago B; Negahban A
    Bioanalysis; 2016 Aug; 8(16):1641-4. PubMed ID: 27416917
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel LC-MS approach for the detection of metabolites in DMPK studies.
    Plumb RS; Mather J; Little D; Rainville PD; Twohig M; Harland G; Kenny DJ; Nicholson JK; Wilson ID; Kass IJ
    Bioanalysis; 2010 Oct; 2(10):1767-78. PubMed ID: 21083328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HRMS in DMPK.
    Korfmacher W; Ramanathan R
    Bioanalysis; 2016 Aug; 8(16):1635-7. PubMed ID: 27487383
    [No Abstract]   [Full Text] [Related]  

  • 4. Technologies and strategies to characterize and quantitate metabolites in drug discovery and development.
    Ravindran S; Jadhav A; Surve P; Lonsane G; Honrao P; Nanda B
    Biomed Chromatogr; 2014 Nov; 28(11):1547-53. PubMed ID: 25175001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of mass spectrometry for in-vitro ADME assays.
    Chu I; Nomeir AA
    Curr Drug Metab; 2006 Jun; 7(5):467-77. PubMed ID: 16787156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of high-resolution mass spectrometry to investigate a metabolite interference during liquid chromatography/tandem mass spectrometric quantification of a small molecule in toxicokinetic study samples.
    Furlong M; Bessire A; Song W; Huntington C; Groeber E
    Rapid Commun Mass Spectrom; 2010 Jul; 24(13):1902-10. PubMed ID: 20533320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrophilic interaction liquid chromatography-tandem mass spectrometry for drug development.
    Hsieh Y
    Curr Drug Discov Technol; 2010 Sep; 7(3):223-31. PubMed ID: 20843291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing the analytical throughput challenges in ADME screening using rapid ultra-performance liquid chromatography/tandem mass spectrometry methodologies.
    Plumb RS; Potts WB; Rainville PD; Alden PG; Shave DH; Baynham G; Mazzeo JR
    Rapid Commun Mass Spectrom; 2008 Jul; 22(14):2139-52. PubMed ID: 18543375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-resolution mass spectrometry will dramatically change our drug-discovery bioanalysis procedures.
    Korfmacher W
    Bioanalysis; 2011 Jun; 3(11):1169-71. PubMed ID: 21649491
    [No Abstract]   [Full Text] [Related]  

  • 10. Mass spectrometry imaging in drug development.
    Nilsson A; Goodwin RJ; Shariatgorji M; Vallianatou T; Webborn PJ; Andrén PE
    Anal Chem; 2015 Feb; 87(3):1437-55. PubMed ID: 25526173
    [No Abstract]   [Full Text] [Related]  

  • 11. Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.
    Katsila T; Siskos AP; Tamvakopoulos C
    Mass Spectrom Rev; 2012; 31(1):110-33. PubMed ID: 21698655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput liquid chromatography/mass spectrometry method for the quantitation of small molecules using accurate mass technologies in supporting discovery drug screening.
    Ding X; Ghobarah H; Zhang X; Jaochico A; Liu X; Deshmukh G; Liederer BM; Hop CE; Dean B
    Rapid Commun Mass Spectrom; 2013 Feb; 27(3):401-8. PubMed ID: 23280971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An introduction to hybrid ion trap/time-of-flight mass spectrometry coupled with liquid chromatography applied to drug metabolism studies.
    Liu ZY
    J Mass Spectrom; 2012 Dec; 47(12):1627-42. PubMed ID: 23280752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
    Tolonen A; Turpeinen M; Pelkonen O
    Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hazards in chromatographic bioanalysis method development and applications.
    Hooshfar S; Bartlett MG
    Biomed Chromatogr; 2017 Jan; 31(1):. PubMed ID: 27696464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Application of Mass Spectrometry in Drug Metabolism and Pharmacokinetics.
    Lee JY; Kim SK; Lee K; Oh SJ
    Adv Exp Med Biol; 2021; 1310():533-550. PubMed ID: 33834449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging and spatially resolved quantification of drug distribution in tissues by mass spectrometry.
    Prideaux B; Lenaerts A; Dartois V
    Curr Opin Chem Biol; 2018 Jun; 44():93-100. PubMed ID: 29957376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of hyphenated chromatography-mass spectrometry techniques in exploratory drug metabolism and pharmacokinetics.
    Hsieh Y; Korfmacher W
    Curr Pharm Des; 2009; 15(19):2251-61. PubMed ID: 19601826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS.
    Ramanathan R; Jemal M; Ramagiri S; Xia YQ; Humpreys WG; Olah T; Korfmacher WA
    J Mass Spectrom; 2011 Jun; 46(6):595-601. PubMed ID: 21630388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioanalytical hydrophilic interaction chromatography: recent challenges, solutions and applications.
    Xu RN; Rieser MJ; El-Shourbagy TA
    Bioanalysis; 2009 Apr; 1(1):239-53. PubMed ID: 21083199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.